company background image
CYAD logo

Celyad Oncology ENXTBR:CYAD Stock Report

Last Price

€0.35

Market Cap

€14.7m

7D

1.1%

1Y

-58.1%

Updated

27 Mar, 2024

Data

Company Financials

CYAD Stock Overview

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer.

CYAD fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Celyad Oncology SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Celyad Oncology
Historical stock prices
Current Share Price€0.35
52 Week High€1.28
52 Week Low€0.35
Beta1.3
1 Month Change-1.39%
3 Month Change-7.55%
1 Year Change-58.14%
3 Year Change-94.13%
5 Year Change-98.22%
Change since IPO-97.87%

Recent News & Updates

Recent updates

We're Keeping An Eye On Celyad Oncology's (EBR:CYAD) Cash Burn Rate

Dec 31
We're Keeping An Eye On Celyad Oncology's (EBR:CYAD) Cash Burn Rate

Shareholder Returns

CYADBE BiotechsBE Market
7D1.1%4.3%3.5%
1Y-58.1%-2.7%-2.4%

Return vs Industry: CYAD underperformed the Belgian Biotechs industry which returned -1.1% over the past year.

Return vs Market: CYAD underperformed the Belgian Market which returned -1% over the past year.

Price Volatility

Is CYAD's price volatile compared to industry and market?
CYAD volatility
CYAD Average Weekly Movement8.1%
Biotechs Industry Average Movement7.4%
Market Average Movement3.6%
10% most volatile stocks in BE Market7.0%
10% least volatile stocks in BE Market2.5%

Stable Share Price: CYAD's share price has been volatile over the past 3 months.

Volatility Over Time: CYAD's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Belgian stocks.

About the Company

FoundedEmployeesCEOWebsite
200437Michel E. Lussierhttps://www.celyad.com

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets.

Celyad Oncology SA Fundamentals Summary

How do Celyad Oncology's earnings and revenue compare to its market cap?
CYAD fundamental statistics
Market cap€14.71m
Earnings (TTM)-€30.62m
Revenue (TTM)€44.00k

334.3x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CYAD income statement (TTM)
Revenue€44.00k
Cost of Revenue€44.00k
Gross Profit€0
Other Expenses€30.62m
Earnings-€30.62m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Apr 05, 2024

Earnings per share (EPS)-0.74
Gross Margin0%
Net Profit Margin-69,588.64%
Debt/Equity Ratio0%

How did CYAD perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.